FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2077779775> ?p ?o ?g. }

• W2077779775 endingPage "e19" @default.
• W2077779775 startingPage "e19" @default.
• W2077779775 abstract "Background HER2-positive breast cancer accounts for approximately 20% of all cases of breast cancer and has an aggressive metastatic course due to distinct natural history. Brain metastasis is diagnosed in up to 40% of patients with HER2-positive breast cancer and is associated with substantial morbidity and mortality. We aimed to investigate the incidence of brain metastases in patients with HER2-positive breast cancer treated at our institute. Methods Between 1995 and 2009, 513 women with pathologically confirmed HER2-positive breast cancer were identified with the hospital information system. Median age was 45 years (range 20–75 years). The patients’ AJCC stages were: stage I (7%), stage II (58%) and stage III (35%). Histological sub-types were: infiltrating ductal carcinoma (96%), infiltrating lobular carcinoma (2%), and others (2%). Pathological grades were: grade I/II (41%) and grade III (59%). 70% of patients were treated with primary surgery. Chemotherapy regimens were: doxorubicin and taxane-based therapy (75%), doxorubicin-based therapy (5%), CMF (9%), and other regimens (5%), either in a neoadjuvant or adjuvant setting. Only 6% of the patients received trastuzumab therapy. 5% of the patients did not receive any type of chemotherapy or targeted therapy. Post-operative radiotherapy was delivered to 86% of patients. Incidence and median time to brain metastases were determined. Findings Median follow-up duration was 48 months. Patterns of failure were: local (5%), regional (2%), and distant metastases (26%). 14% of patients with distant metastases who did not respond to treatment were found to have brain metastases as first site of relapse. Overall brain metastases were seen in 25% of the patients. Median time to brain metastases was 13 months (range 8–50). Interpretation Our results suggest that the HER2-positive breast cancer sub-type remains more aggressive and is associated with a very high incidence of brain metastases. Future studies should focus on new therapeutic options, such as small molecule tyrosine kinase inhibitors in adjuvant settings, to decrease the incidence of systemic relapse. HER2-positive breast cancer accounts for approximately 20% of all cases of breast cancer and has an aggressive metastatic course due to distinct natural history. Brain metastasis is diagnosed in up to 40% of patients with HER2-positive breast cancer and is associated with substantial morbidity and mortality. We aimed to investigate the incidence of brain metastases in patients with HER2-positive breast cancer treated at our institute. Between 1995 and 2009, 513 women with pathologically confirmed HER2-positive breast cancer were identified with the hospital information system. Median age was 45 years (range 20–75 years). The patients’ AJCC stages were: stage I (7%), stage II (58%) and stage III (35%). Histological sub-types were: infiltrating ductal carcinoma (96%), infiltrating lobular carcinoma (2%), and others (2%). Pathological grades were: grade I/II (41%) and grade III (59%). 70% of patients were treated with primary surgery. Chemotherapy regimens were: doxorubicin and taxane-based therapy (75%), doxorubicin-based therapy (5%), CMF (9%), and other regimens (5%), either in a neoadjuvant or adjuvant setting. Only 6% of the patients received trastuzumab therapy. 5% of the patients did not receive any type of chemotherapy or targeted therapy. Post-operative radiotherapy was delivered to 86% of patients. Incidence and median time to brain metastases were determined. Median follow-up duration was 48 months. Patterns of failure were: local (5%), regional (2%), and distant metastases (26%). 14% of patients with distant metastases who did not respond to treatment were found to have brain metastases as first site of relapse. Overall brain metastases were seen in 25% of the patients. Median time to brain metastases was 13 months (range 8–50). Our results suggest that the HER2-positive breast cancer sub-type remains more aggressive and is associated with a very high incidence of brain metastases. Future studies should focus on new therapeutic options, such as small molecule tyrosine kinase inhibitors in adjuvant settings, to decrease the incidence of systemic relapse." @default.
• W2077779775 created "2016-06-24" @default.
• W2077779775 creator A5001244050 @default.
• W2077779775 creator A5004305859 @default.
• W2077779775 creator A5018324103 @default.
• W2077779775 creator A5027450621 @default.
• W2077779775 creator A5039975332 @default.
• W2077779775 date "2014-05-01" @default.
• W2077779775 modified "2023-09-23" @default.
• W2077779775 title "P0038 Brain metastases in HER2-positive breast cancer patients: A single institute experience" @default.
• W2077779775 doi "https://doi.org/10.1016/j.ejca.2014.03.082" @default.
• W2077779775 hasPublicationYear "2014" @default.
• W2077779775 type Work @default.
• W2077779775 sameAs 2077779775 @default.
• W2077779775 citedByCount "0" @default.
• W2077779775 crossrefType "journal-article" @default.
• W2077779775 hasAuthorship W2077779775A5001244050 @default.
• W2077779775 hasAuthorship W2077779775A5004305859 @default.
• W2077779775 hasAuthorship W2077779775A5018324103 @default.
• W2077779775 hasAuthorship W2077779775A5027450621 @default.
• W2077779775 hasAuthorship W2077779775A5039975332 @default.
• W2077779775 hasConcept C120665830 @default.
• W2077779775 hasConcept C121332964 @default.
• W2077779775 hasConcept C121608353 @default.
• W2077779775 hasConcept C126322002 @default.
• W2077779775 hasConcept C143998085 @default.
• W2077779775 hasConcept C146357865 @default.
• W2077779775 hasConcept C151730666 @default.
• W2077779775 hasConcept C2776694085 @default.
• W2077779775 hasConcept C2777511904 @default.
• W2077779775 hasConcept C2778164965 @default.
• W2077779775 hasConcept C2779013556 @default.
• W2077779775 hasConcept C2779786085 @default.
• W2077779775 hasConcept C509974204 @default.
• W2077779775 hasConcept C530470458 @default.
• W2077779775 hasConcept C61511704 @default.
• W2077779775 hasConcept C71924100 @default.
• W2077779775 hasConcept C86803240 @default.
• W2077779775 hasConceptScore W2077779775C120665830 @default.
• W2077779775 hasConceptScore W2077779775C121332964 @default.
• W2077779775 hasConceptScore W2077779775C121608353 @default.
• W2077779775 hasConceptScore W2077779775C126322002 @default.
• W2077779775 hasConceptScore W2077779775C143998085 @default.
• W2077779775 hasConceptScore W2077779775C146357865 @default.
• W2077779775 hasConceptScore W2077779775C151730666 @default.
• W2077779775 hasConceptScore W2077779775C2776694085 @default.
• W2077779775 hasConceptScore W2077779775C2777511904 @default.
• W2077779775 hasConceptScore W2077779775C2778164965 @default.
• W2077779775 hasConceptScore W2077779775C2779013556 @default.
• W2077779775 hasConceptScore W2077779775C2779786085 @default.
• W2077779775 hasConceptScore W2077779775C509974204 @default.
• W2077779775 hasConceptScore W2077779775C530470458 @default.
• W2077779775 hasConceptScore W2077779775C61511704 @default.
• W2077779775 hasConceptScore W2077779775C71924100 @default.
• W2077779775 hasConceptScore W2077779775C86803240 @default.
• W2077779775 hasLocation W20777797751 @default.
• W2077779775 hasOpenAccess W2077779775 @default.
• W2077779775 hasPrimaryLocation W20777797751 @default.
• W2077779775 hasRelatedWork W1967894062 @default.
• W2077779775 hasRelatedWork W2013223170 @default.
• W2077779775 hasRelatedWork W2020150632 @default.
• W2077779775 hasRelatedWork W2092771806 @default.
• W2077779775 hasRelatedWork W2241466075 @default.
• W2077779775 hasRelatedWork W2432872277 @default.
• W2077779775 hasRelatedWork W2627001382 @default.
• W2077779775 hasRelatedWork W2969515167 @default.
• W2077779775 hasRelatedWork W3030794620 @default.
• W2077779775 hasRelatedWork W3041235120 @default.
• W2077779775 hasVolume "50" @default.
• W2077779775 isParatext "false" @default.
• W2077779775 isRetracted "false" @default.
• W2077779775 magId "2077779775" @default.
• W2077779775 workType "article" @default.